Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Sanfeliu

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
ESMO Open|April 10, 2025
Prevalence and clinical impact of germline pathogenic variants in breast cancer: a descriptive large single-center studyA Rodriguez-Hernandez, O Martínez-Sáez, F Brasó-Maristany, et al.
ESMO Open|June 29, 2024
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancerF Schettini, S Nucera, F Brasó-Maristany, et al.
ESMO Open|January 6, 2026
Erratum to "Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study": [ESMO Open 9 (2024) 103989]F Schettini, F Brasó-Maristany, T Pascual, et al.
ESMO Open|September 25, 2025
Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancerB Walbaum, O Martínez-Sáez, F Brasó-Maristany, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2023
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative studyM Oliveira, C Falato, J M Cejalvo, et al.
ESMO Open|January 7, 2025
Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancerL Angelats, L Paré, C Rubio-Perez, et al.
ESMO Open|October 1, 2025
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trialE Seguí, F Brasó-Maristany, T Pascual, et al.
ESMO Open|March 7, 2024
Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancerM Marín-Aguilera, P Jares, E Sanfeliu, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world studyO Martínez-Sáez, M Tapia, M Marín-Aguilera, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 17, 2024
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapyM Martín, S R Stecklein, O Gluz, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
ESMO Open|April 10, 2025
Prevalence and clinical impact of germline pathogenic variants in breast cancer: a descriptive large single-center studyA Rodriguez-Hernandez, O Martínez-Sáez, F Brasó-Maristany, et al.
ESMO Open|June 29, 2024
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancerF Schettini, S Nucera, F Brasó-Maristany, et al.
ESMO Open|January 6, 2026
Erratum to "Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study": [ESMO Open 9 (2024) 103989]F Schettini, F Brasó-Maristany, T Pascual, et al.
ESMO Open|September 25, 2025
Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancerB Walbaum, O Martínez-Sáez, F Brasó-Maristany, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2023
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative studyM Oliveira, C Falato, J M Cejalvo, et al.
ESMO Open|January 7, 2025
Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancerL Angelats, L Paré, C Rubio-Perez, et al.
ESMO Open|October 1, 2025
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trialE Seguí, F Brasó-Maristany, T Pascual, et al.
ESMO Open|March 7, 2024
Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancerM Marín-Aguilera, P Jares, E Sanfeliu, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world studyO Martínez-Sáez, M Tapia, M Marín-Aguilera, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 17, 2024
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapyM Martín, S R Stecklein, O Gluz, et al.
Pageof 2